Postdoctoral positions immediately available
The progressive muscular dystrophy group, Genethon

Combined therapy in Duchenne Muscular Dystrophy

Environment

The Richard's lab is focused on the development of gene-therapy approaches for Limb Girdle and uchenne muscular dystrophy (LGMD and DMD). In Duchenne muscular dystrophy, our lab recently characterized the perturbations of lipid metabolism (Amor et al. 2021) and molecular mechanism of mitochondrial dysfunction (Vu Hong et al. 2021a and Vu Hong et al. 2021b). Present studies are focused further on the molecular mechanisms of these perturbations and on the development of gene therapy and drug-based approaches for their counteraction.

Position and project

Under the responsibility of Dr **David Israeli**, the candidate will investigate and optimize a therapeutic approach in a animal models for Duchenne muscular dystrophy, based on a combination of gene therapy and metabolic normalization.
Under the responsibility of the PI, he/she will be responsible for designing, developing and implementing experimental protocols, working with animal models, present research results, and preparing papers.

Requirements and qualifications

- PhD: Obtained between 2019 and 2021.
- Skills: Talented and motivated team-oriented scientist.
- Background: molecular and cellular biology, bioinformatics, *in vivo* experimentation, a highly developed organizational sense.

Terms

Two-years INSERM-funded postdoctoral position available in **Isabelle Richard's** lab in Genethon, INSERM UMR_S951, Paris-Saclay University.

How to apply

Please provide, a CV, motivation and reference letters before 1st May 2022 to:

Dr David Israeli
Progressive Muscular Dystrophy unit
Genethon, INSERM UMR_S951
Evry University, Paris-Saclay University
Israeli@genethon.fr

Related recent publications

1. Sanson, M.; Vu Hog, A.; Massourides, E.; Bourg, N.; Suel, L.; Amor, F.; Corre, G.; Bénit, P.; Barthelemy, I.; Blot, S.; et al. miR-379 links glucocorticoid treatment with mitochondrial response in Duchenne muscular dystrophy. *Sci. Rep.* **2020**, *10*, 9139, doi:10.1038/s41598-020-66016-7.

2. Amor, F.; Vu Hong, A.; Corre, G.; Sanson, M.; Suel, L.; Blaie, S.; Servais, L.; Voit, T.; Richard, I.; Israeli, D.; et al. Cholesterol metabolism is a potential therapeutic target in Duchenne muscular dystrophy. *J. Cachexia. Sarcopenia Muscle* **2021**, *12*, 677–693, doi:10.1002/jcsm.12708.

3. Vu Hong, A.; Sanson, M.; Richard, I.; Israeli, D.; Hong, A.V.; Sanson, M.; Richard, I.; Israeli, D. A revised model for mitochondrial dysfunction in Duchenne muscular dystrophy. *Eur. J. Transl. Myol.* **2021**, doi:10.4081/EJTM.2021.10012.

4. Vu Hong, A.; Bourg, N.; Sanatine, P.; Poupiot, J.; Charton, K.; Gicquel, E.; Massourides, E.; Spinazzi, M.; Richard, I.; Israeli, D. Dlk1-Dio3 cluster miRNAs regulate mitochondrial functions in Duchenne muscular dystrophy. *bioRxiv* **2021**, 2021.10.20.464950, doi:10.1101/2021.10.20.464950.

5. Bourg, N.; Vu Hong, A.; Lostal, W.; Jaber, A.; Guerchet, N.; Tanniou, G.; Bordier, F.; Bertil-Froidevaux, E.; Georger, C.; Daniele, N.; et al. Co-Administration of Simvastatin Does Not Potentiate the Benefit of Gene Therapy in the mdx Mouse Model for Duchenne Muscular Dystrophy. *Int. J. Mol. Sci. 2022, Vol. 23, Page 2016* **2022**, *23*, 2016, doi:10.3390/IJMS23042016.